Apellis Pharmaceuticals

ISIN US03753U1060

 | 

WKN A2JAAW

Market cap (in EUR)
2,688 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 2,688 m
EPS, EUR 0.27
P/B ratio 7.8
P/E ratio 83.8
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 722 m
Net income, EUR -183 m
Profit margin -25.32%

What ETF is Apellis Pharmaceuticals in?

There are 4 ETFs which contain Apellis Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Apellis Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.22%
Equity
United States
Health Care
Biotech
44
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
491
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.00%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.03%
Equity
United States
Small Cap
180
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.